Anonymized individual participant data from the Salford Lung Study, annotated CRF, protocol, reporting and analysis plan, dataset specification, associated raw dataset, analysis-ready dataset, and clinical study report are available for research proposals SLS Asthma - Primary Effectiveness Analysis (PEA) - This population is defined as all ITT subjects (all randomised subjects who receive at least one prescription of study medication [e.g. FF/VI or Usual Care]) who have an ACT total score of < 20 at baseline (Day 0). This population will be based on the treatment to which the subject was randomised. SLS COPD - Primary Effectiveness Analysis (PEA) - This population comprised all ITT subjects (all randomised subjects who received at least one prescription for study medication [e.g. FF/VI or usual care] who had at least one moderate/severe exacerbation in the year prior to Visit 2 (randomisation), as recorded on the eCRF.
asthma control copd exacerbations pragmatic trial